Quick Comparison
| Orforglipron | VK2735 | |
|---|---|---|
| Half-Life | Approximately 29-49 hours, supporting once-daily oral dosing | Approximately 144-168 hours (6-7 days), supporting once-weekly dosing |
| Typical Dosage | Phase 3 trials: 3 mg oral once daily as the starting dose, escalated every 4 weeks to maintenance doses of 12, 24, or 36 mg once daily. Can be taken at any time of day, with or without food and water — a significant practical advantage over Rybelsus. | Phase 2 (subcutaneous): doses of 2.5, 5, 10, and 15 mg once weekly with stepwise escalation. The 15 mg arm produced the maximum weight loss of 14.7% at 13 weeks. Oral formulation in Phase 1: 30-100 mg daily, dose escalation ongoing. |
| Administration | Oral (tablet, once daily, no food or water restrictions) | Subcutaneous injection (once weekly); oral tablet formulation in earlier development |
| Research Papers | 5 papers | 1 papers |
| Categories |
Mechanism of Action
Orforglipron
Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor through binding outside the orthosteric peptide-binding pocket — a true biased GLP-1 receptor agonist rather than a structural mimic of native GLP-1. Because it is a small molecule rather than a peptide, it is not destroyed by gastric acid or proteolytic enzymes in the gut, which is why it can be taken orally without the strict fasting and water-restriction requirements that limit semaglutide's oral formulation (Rybelsus).
Receptor activation triggers the same downstream signalling cascades as injectable GLP-1 agonists: stimulation of glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, slowing of gastric emptying, and central appetite suppression through hypothalamic and brainstem GLP-1 receptors. Importantly, orforglipron's biased agonism profile favours G-protein signalling over beta-arrestin recruitment, which preclinical data suggests may reduce receptor desensitisation over chronic dosing.
The pharmacokinetic profile gives it a half-life of roughly 29-49 hours, comfortably supporting once-daily oral dosing with stable plasma concentrations. In Phase 2 obesity trials, orforglipron produced approximately 14.7% mean body weight reduction at 36 weeks at the highest dose tested. Phase 3 results in 2026 (ACHIEVE-1 for type 2 diabetes, ATTAIN-1 and ATTAIN-2 for obesity) have positioned it as the leading candidate to be the first true oral GLP-1 with weight-loss efficacy approaching that of weekly injectables, removing one of the main barriers to GLP-1 therapy adoption.
VK2735
VK2735 is a once-weekly subcutaneous dual GLP-1/GIP receptor agonist with a structure optimised for high potency and a clean tolerability profile. Dual incretin receptor activation produces complementary effects on appetite, glucose handling, and energy expenditure: GLP-1 receptor agonism delivers central appetite suppression through hypothalamic arcuate-nucleus signalling, slows gastric emptying, and triggers glucose-dependent insulin secretion, while GIP receptor activation amplifies the insulin response, supports beta-cell function, and modulates adipose tissue lipid handling.
The molecule's pharmacokinetic profile delivers sustained receptor exposure across a one-week dosing interval, achieved through structural modifications that enable albumin binding and resistance to proteolytic degradation. In the Phase 2 VENTURE trial, the 15 mg dose produced 14.7% mean body weight loss at 13 weeks — the fastest early weight loss observed for any obesity drug, with the loss curve still descending steeply at trial end. This rapid trajectory suggests substantially greater total weight loss would be achievable with longer dosing, and Phase 3 VANQUISH trials launched in 2026 are testing 68-week treatment durations to characterise the full magnitude of effect.
Viking is also developing an oral tablet formulation of VK2735 in parallel, which entered Phase 1 in 2024-2025. If both formulations succeed, Viking would have one of the most flexible GLP-1/GIP product profiles on the market — though as a small biotech company it faces significant manufacturing and commercial scaling challenges relative to Lilly and Novo Nordisk.
Risks & Safety
Orforglipron
Common
nausea, vomiting, diarrhea, constipation, dyspepsia. Side-effect frequency in Phase 3 has been comparable to injectable GLP-1 agonists.
Serious
pancreatitis, gallstones, dehydration.
Rare
thyroid C-cell tumour signal as a class warning, severe allergic reactions. Long-term safety still being characterised.
VK2735
Common
nausea, vomiting, diarrhea, constipation, decreased appetite, injection site reactions. Discontinuation rates in Phase 2 were broadly similar to other GLP-1/GIP dual agonists.
Serious
pancreatitis, gallstones, possible muscle mass loss.
Rare
thyroid C-cell tumour class warning, severe allergic reactions. Long-term safety being established in Phase 3.
Full Profiles
Orforglipron →
The first weight loss drug in the GLP-1 class that comes as a daily pill rather than a weekly injection — and unlike Rybelsus, you can take it with food and water. Made by Eli Lilly, it is technically a small molecule rather than a peptide, but it activates the same GLP-1 receptor as semaglutide and tirzepatide. Phase 3 trials in 2026 (ACHIEVE-1 in diabetes, ATTAIN-1 and ATTAIN-2 in obesity) have shown around 14-15% body weight loss. Likely to be the first oral GLP-1 to compete on weight loss with the injectables.
VK2735 →
Viking Therapeutics' once-weekly weight loss injection that, like tirzepatide, hits both the GLP-1 and GIP receptors. In a 13-week Phase 2 trial it produced 14.7% mean body weight loss — the steepest early loss curve recorded for any obesity drug — and Phase 3 VANQUISH trials began in 2026. An oral tablet version is also in earlier development. Viking is one of the only small biotech companies competing directly with Lilly and Novo Nordisk in the GLP-1 space.